Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations

NEW YORK —April 1, 2024 —Actinium Pharmaceuticals, Inc. , a trailblazer in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapy treatments, is at the forefront of oncology innovation with its latest venture into improving CAR T-cell therapy. The company announced a partnership with the University of Texas Southwestern Medical Center (UT Southwestern) to initiate a clinical trial focused on their pioneering product, Iomab-ACT, as a conditioning agent before CAR T-cell therapy. This move not only underscores Actinium’s commitment to enhancing cancer treatment but also marks a significant stride towards reducing the toxicities associated with current conditioning regimens.

Iomab-ACT: A Leap Forward

Iomab-ACT is designed to replace the chemotherapy conditioning regimens that are presently used before cell and gene therapies. These traditional regimens are known for their significant toxicities, such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), which can limit patient access to CAR-T therapies and result in poorer outcomes. Iomab-ACT aims to provide targeted lymphodepletion with minimal incidences of these major toxicities, potentially increasing patient access to CAR-T therapies and improving their efficacy.

A Pivotal Moment for Actinium

Sandesh Seth, Actinium’s Chairman and CEO, highlights the importance of the Iomab-ACT program, viewing it as a potential game-changer in the practice of cellular therapies. With the CAR-T and gene therapy market expected to nearly double by 2030, reaching approximately 93,000 patients annually in the U.S. alone, Iomab-ACT positions Actinium at the cutting edge of targeted radiotherapy applications.

Collaborative Clinical Trials

Dr. Avinash Desai, Actinium’s Chief Medical Officer, expresses excitement over the collaboration with UT Southwestern for this groundbreaking trial. The study aims to demonstrate Iomab-ACT’s ability to reduce CAR-T related toxicities, such as ICANS and CRS, and to improve overall therapy efficacy. Preliminary results from a phase 1 trial with Memorial Sloan Kettering’s CD19 CAR-T therapy have shown promising outcomes, laying the groundwork for the upcoming study with a commercial CAR-T therapy.

The Future of Cellular Therapy Conditioning

The development of Iomab-ACT is part of Actinium’s broader vision to revolutionize conditioning for cellular and gene therapies. With a rapidly expanding pipeline of CAR-T and gene therapies, the potential patient population for these treatments is expected to grow significantly. Actinium’s continued development of targeted conditioning programs like Iomab-ACT holds the promise of enhancing access and outcomes for patients undergoing these transformative treatments.

Actinium Pharmaceuticals: A Visionary in Oncology

Actinium Pharmaceuticals stands as a leader in developing targeted radiotherapies aimed at improving survival for patients who have exhausted conventional oncology treatments. With advanced pipeline candidates like Iomab-B and Actimab-A showing potential in extending survival outcomes for acute myeloid leukemia, Actinium is poised to make significant contributions to the field of oncology.

For traders and investors, Actinium’s innovative approach to CAR T-cell therapy conditioning represents a compelling investment opportunity. The company’s focus on improving the efficacy and accessibility of CAR-T and gene therapies could position it as a key player in the rapidly growing oncology market. As Actinium continues to advance its pipeline and forge strategic partnerships, its potential for growth and impact in the biopharmaceutical industry remains significant.

Significant Upside Potential

Based on 4 Wall Street analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $30.50 with a high forecast of $50.00 and a low forecast of $16.00. The average price target represents a 289.53% change from the last price of $7.83.

Stay tuned for updates on this exciting journey, as Actinium Pharmaceuticals continues to redefine the landscape of cancer treatment and cellular therapy.

On Friday, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) saw a price increase of 0.06 USD (5.45%), reaching 1.16 USD with a trading volume of 26.13M against the previous 22.65M, valuing the company at 2.50B USD. Nikola Corporation (NASDAQ: NKLA) experienced a surge of 0.13 USD (14.40%) to 1.04 USD, with a massive trade volume of 163.84M over the prior 93.28M, bringing its valuation to 1.39B USD. OPKO Health, Inc. (NASDAQ: OPK) climbed by 0.13 USD (12.15%) to 1.2 USD, trading 28.90M shares compared to 15.28M previously, and is now worth 836.39M USD. Bitfarms Ltd. (NASDAQ: BITF) increased by 0.07 USD (3.24%) to 2.23 USD with a volume of 38.33M versus 26.99M, with the market capitalization at 747.56M USD. Lastly, Tellurian Inc. (NYSEAMERICAN: TELL) went up by 0.07 USD (11.40%) to 0.6614 USD, on a volume of 47.17M compared to 38.61M before, totaling a valuation of 517.47M USD.

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated three thousand and five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 20th to April 1st, 2024. We own zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Sources:

https://www.tipranks.com/stocks/atnm/forecast#google_vignette

https://finance.yahoo.com/news/actinium-announces-clinical-trial-study-111800504.html

Media Contact:

Company Name: Investor Brand Media

Contact Person: Ash K

Email: [email protected]

Phone: (954) 593-5597

Website: https://investorbrandmedia.com/